Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000657119 | SCV000293912 | uncertain significance | not provided | 2024-04-24 | criteria provided, single submitter | clinical testing | Reported as a variant of uncertain significance in a patient with epilepsy (PMID: 36539902); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; In silico analysis suggests this variant may impact gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; This variant is associated with the following publications: (PMID: 36539902) |
Eurofins Ntd Llc |
RCV000657119 | SCV000337702 | uncertain significance | not provided | 2017-07-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001079212 | SCV000559271 | benign | Neuropathy, hereditary sensory and autonomic, type 2A; Generalized epilepsy with febrile seizures plus, type 7 | 2025-01-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002436062 | SCV002753784 | likely benign | Inborn genetic diseases | 2021-01-07 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV004532985 | SCV004751936 | likely benign | SCN9A-related disorder | 2019-07-12 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |